BCRX BioCryst Pharmaceuticals Inc
Company Analysis
Latest News
🟢 BioCryst Pharmaceuticals is trading 8.65% up today after beating Q2 estimates and raising its FY26 outlook
BioCryst Pharmaceuticals is trading at $9.80 (+8.65%) following a strong Q2 2026 earnings report and an upward revision to its full-year guidance. • The...
BioCryst Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
BioCryst Pharmaceuticals is expected to report Q2 2026 revenue of $183.28 million and an EPS of $0.14, with its current stock price of $8.98 trading...
🔴 BioCryst Pharmaceuticals is trading 5.6% down today, extending a multi-day slide without a clear catalyst
BioCryst Pharmaceuticals is trading 5.6% down at $8.72 in pre-market, extending its recent multi-day slide despite a lack of fresh company-specific news or...
🔴 BioCryst Pharmaceuticals is trading 6.05% down today without a clear company-specific catalyst
BioCryst Pharmaceuticals is trading at $9.00 (-6.05%) in pre-market, appearing to reverse recent technical momentum in the absence of fresh company-specific...
🟢 BioCryst Pharmaceuticals is trading 5% up today on technical momentum and a broad biotech rally
BioCryst Pharmaceuticals is trading up 4.9% at $9.80 as traders extend a multi-week technical uptrend. • No fresh company-specific news or major catalysts...
🟢 BioCryst Pharmaceuticals is trading 4.9% up today as technical momentum extends multi-week uptrend
BioCryst Pharmaceuticals is trading at $9.80 (4.9%) up in pre-market as technical momentum extends a multi-week uptrend in the absence of fresh company...
🔴 BioCryst Pharmaceuticals is trading 5.2% down
BioCryst Pharmaceuticals is trading at $9.23, down 5.2% from a comparison close of $9.74 during regular trading. This is a price-action follow-up, so a...
JPMorgan Gives BioCryst a Lukewarm Blessing at $12 — But Can a Single Drug Launch Justify the Bet?
Shares of BioCryst Pharmaceuticals surged 7.1% in early trading after JPMorgan resumed coverage with a Neutral rating and a $12 price target, snapping a...
🟢 BioCryst Pharmaceuticals is trading 7.1% up today after JPMorgan resumed coverage with a $12 price target
BioCryst Pharmaceuticals is trading 7.1% up at $10.43 in pre-market sessions after JPMorgan resumed coverage with a Neutral rating and a $12 price target. •...
🟢 BioCryst Pharmaceuticals is trading 5.5% up today as JPMorgan resumes coverage with a $12 price target
BioCryst Pharmaceuticals is trading 5.5% up at $10.27 in after-hours trading, rebounding from recent declines as the company sees renewed analyst focus. •...
🟢 BioCryst Pharmaceuticals Inc is trading 6.46% up in pre-market
BCRX is trading at $10.55, up 6.46% in pre-market.